Impact of Payment Reform on Chemotherapy at the End of Life

Journal of Oncology Practice
Colla CH, Morden NE, Skinner JS, Hoverman JR, Meara E

In physician offices, where drugs generate the majority of revenue and prescribing patterns can determine physician income, use of chemotherapy at the end of life fell significantly after reimbursement reductions; no concurrent change occurred in hospital outpatient departments. These results suggest that payment reform may be used to better align appropriate financial incentives with better quality of care.